Literature DB >> 3370312

Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species.

H Berger1, S V Pizzo.   

Abstract

Conditions were defined for the derivatization of recombinant tissue plasminogen activator (rt-PA) with polyethylene glycol (PEG) so as to retain functional activity as a possible means of producing a t-PA species with a prolonged circulating lifetime. Derivatives with a wide range of retention of activities were prepared by varying the concentration and species of activated PEG. The specific activities of the PEG-rt-PA derivatives were dependent on the method of assay. Assays using preformed fibrin gave higher estimates of retention of activity than assays using soluble components. Plasma elimination studies in mice and rats indicated prolonged circulating lifetimes for the radiolabeled PEG-rt-PA derivatives after a rapid clearance and distribution phase; however, the disappearance of functional activity was much more rapid than the disappearance of radiolabeled material. The PEG-rt-PA derivatives appeared to accumulate in tissues above their interstitial fluid concentrations and were rapidly inactivated, apparently by reaction with the plasma protease inhibitors. These results were consistent with the inactivation of the PEG-rt-PA derivatives in rat plasma in vitro. A somewhat longer half-life (t1/2) of the one derivative studied was observed in dogs (t1/2, 16 minutes) as compared with the rat (t1/2, five minutes). This was sufficient to confer thrombolytic activity upon the derivative (administered by bolus injection) in contrast to native rt-PA. The potential of PEG-modified rt-PA as a long-lived thrombolytic agent in humans will depend, however, on whether there will be a further extension of the t1/2 because of a reduction in clearance and/or a reduction in the rate of inactivation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370312

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Advanced drug delivery systems for antithrombotic agents.

Authors:  Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

Review 2.  Polymer conjugates. Pharmacokinetic considerations for design and development.

Authors:  R Duncan; F Spreafico
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

3.  Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.

Authors:  Andrzej S Pitek; Yunmei Wang; Sahil Gulati; Huiyun Gao; Phoebe L Stewart; Daniel I Simon; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2017-09-26       Impact factor: 4.939

4.  Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.

Authors:  Shahriar Absar; Kamrun Nahar; Young Min Kwon; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2013-03-07       Impact factor: 4.200

Review 5.  Engineered microparticles and nanoparticles for fibrinolysis.

Authors:  Dante Disharoon; David W M Marr; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2019-10-07       Impact factor: 5.824

6.  Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle.

Authors:  Jyh-Ping Chen; Pei-Ching Yang; Yunn-Hwa Ma; Su-Ju Tu; Yu-Jen Lu
Journal:  Int J Nanomedicine       Date:  2012-09-27

7.  Altered biodistribution of an antibody--enzyme conjugate modified with polyethylene glycol.

Authors:  E A Eno-Amooquaye; F Searle; J A Boden; S K Sharma; P J Burke
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

8.  Investigation of chitosan-g-PEG grafted nanoparticles as a half-life enhancer carrier for tissue plasminogen activator delivery.

Authors:  Arezoo Khosravi; Hadi Baharifar; Mohamad Hasan Darvishi; Ali Akbar Karimi Zarchi
Journal:  IET Nanobiotechnol       Date:  2020-12       Impact factor: 1.847

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.